You are here: Industry Insights > M&A

News List

In Two Months, Biotech Startups Raised More Money Than In All Of 2013 forbes
March 13, 2018
If there are any worries about the future of biotech, don't tell the venture capitalists.
Healthcare M&A outlook bright for 2018: Analysts biospectrumasia
March 08, 2018
After a subdued 2017, analysts and industry experts predict 2018 to be a robust year for healthcare M&A
New FTC rules hurt M&A prospects for hard-hit generics players fiercepharma
February 27, 2018
The generics sector has been looking to M&A as a way to combat the pricing pressure crushing top lines around the industry. But that strategy just got a whole lot less attractive.
6 Promising Biopharmas With Major Catalysts in 2018 biospace
January 30, 2018
Not only is the biopharma market expected to be a hot one for mergers and acquisitions this year, but it’s expected to be hot for stocks as well.
Flushed With Cash, Shanghai Pharma Hunts for M&A in the U.S. and Europe biospace
January 25, 2018
Shanghai Pharmaceuticals is looking to buy companies in the U.S. and Europe. This acquisition strategy is part of its two-pronged approach to growth, along with internal research and development.
Biotech M&A In 2018: A Tsunami Or A Ripple? forbes
January 23, 2018
Possible biotech M&A targets in 2018 include gene therapy technology and cancer drug makers.
2 Under-the-Radar Pharma M&A Targets for 2018 biospace
January 12, 2018
Many analysts are looking for a good year for biopharma stocks in 2018. Some of it’s just general optimism at the beginning of the year, but others are pointing to the changes to the tax code that will eventually free up a lot of corporations’ cash.
Allergan hits its already battered Irvine site with another round of job cuts fiercepharma
August 30, 2017
Allergan's Irvine campus was the site of hundreds of job cuts in 2014 and 2015.
Small growth for Big Pharma's workforce a decade with more restructuring fiercepharma
August 23, 2017
Top drugmakers have hired since 2007, but they've also laid off workers in the wake of major M&A deals.
Which M&A made our best-and-worst ballot? Vote for the deals of the decade fiercepharma
August 16, 2017
Choose among 20-plus deals—big, like the GSK-Novartis asset swap, and smaller buys such as Bristol-Myers' Medarex buyout—for best and worst of the past 10 years.

Previous page 1 2 3 4 5 6 7 Next page